Connect with us


People with HIV/AIDS in Ropla no more in hide




KATHMANDU — Many people living with HIV/AIDS in various places across Rolpa districts lately have begun to go public about their HIV status.

Thanks to the awareness drive and counseling conducted by the local governmental and non-governmental agencies about this disease, those keeping their infection in dark fearing the social stigma are gradually bringing their HIV positive status to light.

There are altogether 49 such people recorded in the district, according to Rolpa Plus. Among them, 15 are currently outside of the district due to their professional responsibility, while among the remaining ones in the district, 20 are female while 14 are male.

ALSO READ :  Mother's diabetes may be tied to baby's autism risk

“Every year, around two or three new HIV infected people are recorded for some years,” shared Radha BK. President of the Red Plus, a local agency offering treatment against HIV/AIDS.

Last winter alone, three new HIV patients came in contact with it.

President BK said that of those HIV patients in the district, 32 are availing treatment and other services offered by Red Plus while two are not willing to receiving any treatment fearing the social shame.

According to BK, 14 people in the district were recorded losing their lives to HIV infection. Three children have contracted HIV infection from their parents while 31 are affected with it.

Various social organizations have been assisting HIV/AIDS children in their education.

Continue Reading


Diabetes drug might ease heart failure risk

Gorkha Post



A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.

According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.

Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.

The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.

Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.

ALSO READ :  Saturated fat should be no more than 10 percent of diet : WHO

“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.

“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.

Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.

Their risk of kidney failure and death from kidney failure also fell, researchers noted.

Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.

With Inputs from HealthDay

Continue Reading